Alvotech and Advanz Pharma Expand Strategic Biosimilar Alliance Across Europe, Targeting $13.8B+ Market
Alvotech and Advanz Pharma have announced an expansion of their strategic commercial partnership to include…
Alvotech and Advanz Pharma Expand Strategic Biosimilar Alliance Across Europe, Targeting $13.8B+ Market
Alvotech and Advanz Pharma have announced an expansion of their strategic commercial partnership to include three additional biosimilar candidates in Europe. This action strengthens their combined presence in one of the most active biosimilar marketplaces in the globe. Key Highlights of the Agreement: Market Impact: This expansion increases the total number of biosimilars under the…
Biogen and City Therapeutics Forge $1 Billion+ RNAi Partnership to Transform CNS Drug Development
Biogen Inc. and City Therapeutics, Inc., a pioneer in next-generation RNAi, have formed a strategic research partnership to develop RNA interference (RNAi)-based therapeutics for central nervous system (CNS) disorders. Deal Highlights: City Therapeutics’ innovative RNAi trigger engineering and Biogen’s global medication development and commercialization capabilities are combined in this high-impact collaboration. The initial focus will…
XPENG Launches Electric Vehicles in Poland
XPENG, has officially made its debut in the Polish market. The company unveiled its cutting-edge lineup during a high-profile launch event at the MOXO club in Warsaw, which attracted a large audience from the automotive industry, business community and media. Center stage were three of XPENG’s advanced electric models the G9 SUV, G6 coupe SUV…
Graco Inc, had announced an expansion of its QUANTM pump line, aimed at boosting industrial efficiency and reliability.
Graco Inc, had announced an expansion of its QUANTM pump line, aimed at boosting industrial efficiency and reliability. The update introduces a new 480V input power option along with XTREME TORQUE (XT) motor technology, enhancing performance for demanding manufacturing environments. The QUANTM electric double diaphragm (EODD) pumps are built to support the evolving needs of…
Probiotic Revolution for Anxiety Relief: Unlocking the Connection Between Gut Bacteria and Mental Health
On February 17, 2025, Researchers from Duke-NUS Medical School and the National Neuroscience Institute uncovered a crucial connection between gut microbes and anxiety-related behavior. Their latest study, published in EMBO Molecular Medicine, highlights how microbial metabolites, specifically indoles, directly impact brain activity linked to anxiety. This groundbreaking discovery opens new possibilities for probiotic-based treatments aimed…
Key Developments In The Pharmaceutical Industry 2025
Last week, several significant events in the pharmaceutical industry have captured attention, signaling important shifts in investment strategies, acquisitions, and growth phases for top companies in Asia. From strategic reorientation to major acquisitions, here’s a closer look at the key developments shaping the sector. Astellas Shifts Investment Focus Astellas, known for its cutting-edge research in…
Pfizer’s Adcetris Receives FDA Approval For Treating Large B-Cell Lymphoma
Pfizer’s Adcetris (brentuximab vedotin) has secured a new FDA approval to treat patients with large B-cell lymphoma (LBCL), marking another milestone for the blood cancer drug. More than 13 years after its initial approval, Adcetris is now authorized for use in combination with lenalidomide and rituximab for certain LBCL patients who have undergone at least…
Merck KGaA In Advanced Talks To Acquire Springworks Therapeutics Amid Fda Decision On Key Drug
Merck KGaA, the German biopharma giant, is in advanced discussions to acquire SpringWorks Therapeutics, a Connecticut-based company specializing in cancer and rare disease treatments. The news, first reported by Reuters, comes as SpringWorks awaits an important FDA approval decision on its MEK inhibitor, mirdametinib, expected later this month. The potential acquisition is significant, as SpringWorks…
Zimmer Biomet to Acquire Paragon 28 in $1.2 Billion Deal to Expand Orthopedic Portfolio
Overview On 28th January 2025, Zimmer Biomet Holdings, Inc., a leading global medical technology company, has announced a definitive agreement to acquire Paragon 28, Inc., a specialist in foot and ankle orthopedic devices, in a $1.2 billion transaction. The acquisition will be executed through an upfront cash payment of $13.00 per share, representing an equity…
Huawei and JAC Expand Ultra-Luxury EV Lineup with Maextro, Strengthening China’s Automotive Dominance
On January 29, 2025, Huawei and Chinese automobile manufacturer JAC announced the development of two new models under their ultra-luxury brand, Maextro. This initiative follows the unveiling of their first model, the Maextro S800, which debuted at a Huawei press conference in November 2024. The S800, a full-sized luxury sedan, boasts a starting pre-sale price…
Inogen and Yuwell Partnered to Revolutionize Global Respiratory Care
Inogen, Inc. announced a strategic collaboration with Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (Yuwell), enhancing Inogen’s product offerings, expanding its global presence, and bolstering its innovation pipeline. As part of this agreement, Yuwell will distribute specific respiratory products through Inogen in the United States and other territories, while Inogen will capitalize on the…
CRISPR Gene-Editing Offers Hope For Muscular Dystrophy Treatment
Researchers at the Experimental and Clinical Research Center (ECRC) in Berlin have made a significant breakthrough in the development of a gene-editing therapy for muscular dystrophy, specifically targeting limb-girdle muscular dystrophy (LGMD). Led by Professor Simone Spuler and Dr. Helena Escobar, this promising approach utilizes CRISPR-Cas9 technology to correct genetic mutations responsible for muscle degeneration…
Three-Drug Cocktail Boosts Car-T Cell Therapy’s Potential In Cancer Treatment
Preclinical research from the University of North Carolina Lineberger Comprehensive Cancer Center has revealed a promising cocktail of three different drugs that could potentially enhance CAR-T (chimeric antigen receptor-T) cell therapy for cancer treatment. This discovery has the potential to significantly improve the production of CAR-T cells for clinical use by boosting the immune system’s…
Takeda Launches Innovation Centre, Aiming To Attract AI-Driven Talent
Takeda, a leading Japanese pharmaceutical company, has announced the launch of its new Innovation Centre, with a strong focus on leveraging artificial intelligence (AI) and digital technologies to drive the next phase of pharmaceutical innovation. The company aims to harness AI to improve drug discovery, optimize clinical trials, and accelerate the development of new therapies,…
Biocon Appeals To Indian Government For Tax Exemption On Cancer And Rare-Disease Drugs In Budget
Biocon, a leading biopharmaceutical company, has urged the Indian government to exempt cancer and rare-disease drugs from taxes in the upcoming Union Budget. This plea is a part of the company’s broader efforts to ensure that life-saving medicines remain affordable for patients battling critical conditions. The company believes that tax exemptions on these specialized drugs…
Trends in Preventive Healthcare – Reviving the Age-Old Practices
“Prevention is better than care” as they say, this age-old phrase has never been more relevant. With the aging population, rising incidence of chronic diseases, and skyrocketing healthcare costs, the public health focus is shifting toward preventive medicine. Several governments across the world are prioritizing public health and investing in preventive healthcare practices. Before a…
Becton, Dickinson and Company (BD) Expands U.S. Manufacturing to Strengthen Medical Device Supply Chain
On January 15, 2025, BD (Becton, Dickinson and Company) Announced additional investments to expand its U.S. manufacturing network, thereby improving the production of critical medical devices such as IV catheters, needles, and syringes. The objective of these endeavors is to fortify the resilience of the supply chain and address the persistent requirements of the U.S….
U.S. Prescription Drug Prices to Rise in 2025, Driven by High-Cost Treatments
The cost of prescription drugs in the U.S. is projected to continue rising in 2025 and beyond, driven by a steady stream of high-cost treatments. A recent survey by TD Cowen, based on feedback from 27 health organizations, pharmacies, and hospitals representing about one-fourth of total U.S. drug spending in 2024 ($179 billion) shows that…
Argon Medical Expands Interventional Oncology Portfolio with SeQure® and DraKon™ Microcatheters
On January 14, 2025, Argon Medical Devices announced the acquisition of the SeQure® and DraKon™ microcatheters from Accurate Medical Therapeutics, Ltd., previously distributed by Guerbet SA. This acquisition bolsters Argon’s offerings for interventional oncology by adding therapeutic devices to its established diagnostic oncology product line, which includes biopsy devices. Microcatheters, including SeQure and DraKon, are…
Biogen Challenges Eli Lilly in the Alzheimer’s Treatment Race with Leqembi vs. Kisunla
As the Alzheimer’s drug market intensifies, Biogen is preparing for a fierce competition against Eli Lilly’s newly approved Alzheimer’s treatment, Kisunla. Biogen’s CEO Chris Viehbacher expressed confidence at the J.P. Morgan Healthcare Conference, stating that his company is ready to “stand our ground” in the Alzheimer’s treatment race, despite the challenge posed by Eli Lilly’s…
- 1
- 2
